Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Drugs In Development, 2022, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Unknown stages are 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hyperglycemia – Overview
Hyperglycemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperglycemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperglycemia – Companies Involved in Therapeutics Development
Auxulin Pharmaceuticals Inc
Boryung Pharmaceutical Co Ltd
FGH BioTech Inc
Guangzhou General Pharmaceutical Research Institute Co Ltd
Protheragen Inc
Hyperglycemia – Drug Profiles
AUX-101 – Drug Profile
Drugs to Inhibit ABHD6 for Metabolic Disorders – Drug Profile
FGH-10019 – Drug Profile
GPCR-targeted Project 014 – Drug Profile
KR-62980 – Drug Profile
Small Molecule to Agonise PPARG and Antagonize AGTR1 for Hyperglycemia and Hypertension – Drug Profile
Small Molecule to Inhibit SGLT2 for Hyperglycemia and Thrombosis – Drug Profile
Small Molecules to Antagonize PST Receptor for Dysglycemic States – Drug Profile
Small Molecules to Inhibit PEPCK for Hyperglycemia – Drug Profile
Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes – Drug Profile
Hyperglycemia – Dormant Projects
Hyperglycemia – Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Hyperglycemia, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Hyperglycemia – Pipeline by Auxulin Pharmaceuticals Inc, 2022
Table 11: Hyperglycemia – Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Table 12: Hyperglycemia – Pipeline by FGH BioTech Inc, 2022
Table 13: Hyperglycemia – Pipeline by Guangzhou General Pharmaceutical Research Institute Co Ltd, 2022
Table 14: Hyperglycemia – Pipeline by Protheragen Inc, 2022
Table 15: Hyperglycemia – Dormant Projects, 2022
Table 16: Hyperglycemia – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Hyperglycemia, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Targets, 2022
Figure 5: Number of Products by Stage and Targets, 2022
Figure 6: Number of Products by Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Mechanism of Actions, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings